SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on ...

Learn about the current medication options for managing type 2 diabetes and chronic kidney disease, including SGLT2 ...

In a study from Korea, adults with type 2 diabetes had a lower risk for autoimmune rheumatic diseases after starting an SGLT2 ...

The scenario of chronic kidney disease (CKD) management has been transformed by the advent of sodium glucose co-transporter-2 ...

Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed. The combined 12-month risk for myocardial infarction (MI), ...

SGLT2 inhibitors show significant benefits in older adults with cardiovascular disease, with consistent benefits across subgroups based on diabetes status or age, a meta-analysis shows.

Orforglipron, a novel oral GLP-1, was superior to dapagliflozin for reducing HbA1c in adults with type 2 diabetes ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide a beneficial choice of treatment for patients with type 2 diabetes (diabetes mellitus/T2DM). It can be used as an alternative for those who ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “Sodium-glucose transport protein 2 (SGLT2) inhibitor ...

The new report compared the benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors with those of other glucose-lowering drugs and found lower rates of heart disease and mortality. A new ...

Compared with placebo, SGLT2 inhibitors reduced heart failure hospitalizations among patients with history of myocardial infarction. Sodium-glucose co-transporter 2 (SGLT2) inhibitors may ...